Dermatology Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape


Posted May 9, 2019 by psmarketresearch2017

Dermatology drugs market is expected to reach $34.5 billion by 2023, according to P&S Intelligence.

 
On the basis of treatment, the dermatology drugs market has been categorized into topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others. Among these, biologics is expected to be the fastest growing category, advancing at CAGR of 9.1% during the forecast period.

Based on drug, the dermatology drugs market has been mainly classified into Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, and Eucrisa. Of these, Humira witnessed the highest demand in the market, majorly among patients suffering from psoriasis.
On the basis of distribution channel, the dermatology drugs market has been categorized into direct, wholesale/retail, and online channels. Of these, the fastest growth in the market during the forecast period is expected from direct distribution channels, with 8.5% CAGR. Besides, the major end users covered under the scope of the study are hospitals, clinics, cosmetic centers, and at-home users, where hospitals generated the highest revenue, amounting to $8.2 billion, in the market in 2017. This can be attributed to the availability of improved healthcare facilities and rising patient base in hospitals globally.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/dermatology-drug-market/report-sample

During the forecast period, the dermatology drugs market is forecasted to witness the fastest growth in APAC, with 9.6% CAGR. This growth can be attributed to the increasing disposable income of people in the region, which is leading to the high adoption of skincare products, including dermatological drugs. Moreover, the increase in the number of skin cancer cases in the region is contributing to the high demand for these drugs.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dermatology-drug-market

Companies operating in the dermatology drugs market are collaborating with other pharmaceutical firms to develop new and innovative products. For instance, in November 2018, Sanofi collaborated with Denali Therapeutics Inc. (Denali), a biopharmaceutical company, for the development of multiple molecules, DNL747 and DNL758, with the potential to treat a range of neurological and systemic inflammatory diseases. Under the agreement, Sanofi will pay $125 million to Denali to study the lead molecule DNL747 in multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis and DNL758 in systemic inflammatory diseases, such as rheumatoid arthritis and psoriasis.

Some of the other key players in the dermatology drugs market are Celgene Corporation, Bausch Health Companies Inc., Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Allergan plc, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Nestlé Skin Health S.A., GlaxoSmithKline plc, Mylan N.V., and LEO Pharma A/S.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By P&S Intelligence
Business Address Block-13, Sector 2, Noida, Uttar Pradesh - 201301 India
Country India
Categories Biotech , Health , Industry
Tags demand , dermatology drugs market , growth , outlook , research report , share , size , trends
Last Updated May 9, 2019